Wassil Nowicky,
Nowicky Pharma/Ukrainian Anti-Cancer Institute, Austria
Biography
Wassil Nowicky (Dipl Ing, Dr techn, DDD rh c) is the Director of Nowicky Pharma and President of the Ukrainian Anti- Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955; with graduation to Diplomingeniueur in 1960 which title was nostrificated in Austria (1975). He became the very first Scientist in the development of the anticancer protonic therapy and is the Inventor of NSC-631570, the anticancer preparation on basis of celandine alkaloids. He used the factor that cancer cells are more negatively charged than normal cells and invented the celandine alkaloid with a positive charge, thanks to which it accumulates in cancer cells very fast. He is the Author of over 300 scientific articles dedicated to cancer research. He is a real Member of the New York Academy of Sciences, Member of the European Union for applied immunology and of the American Association for scientific progress, honorary Doctor of the Yanka Kupala State University of Grodno, Doctor honoris causa of the Open International University for Complementary Medicine in Colombo, Honorary Member of the Austrian Society on the Name of Albert Schweizer. He has received merits of National Guild of the award of Austrian Society.
Abstract
Dendritic cells are immune cells that act as messengers between the innate and adaptive immunity. Their main functions is to process antigen material and present it on the surface to other cells of the immune system, thus functioning as antigenâ€presenting cells and are seen as the most potent population executing this function. In the experiments with the mononuclears from the peripheric blood of healthy persons, the effect of the anti-cancer preparation NSC-631570 (UKRAIN) on the phenotypic and functional properties of dendritic cells was studied. The most prominent induction of the expression of the cell surface molecules CD86 and HLAâ€DR was achieved with NSC-631570 at the lowest and highest concentration, 0.6 μg/mL and 10 μg/mL, respectively. Lipopolysaccharide as standard comparative agent induced similar increase of the cell surface receptors. The proliferation index of the incubated lymphocytes was used as the indicator of the dendritic cells activity. After addition of NSC631570 to the incubated dendritic cells, the lymphocyte proliferation index increased from 22.6% up to 32.30% at 0.6 μg/ mL or 29.34% at 10 μg/mL respectively. These values are similar to the one of 31.82%, i.e. proliferation index achieved at the incubation of lymphocytes with the phytohemagglutinin. The authors concluded dendritic cells incubated with NSC-631570 are strong stimulators of the lymphocyte proliferation. They postulate also NSC-631570 can take an important part in the immune therapy
of cancer.